Resources | NITAG RESOURCE CENTER

2024 ∙ ATAGI

ATAGI statement on Nirsevimab for the prevention of severe disease due to respiratory syncytial virus (RSV) in infants

2021 ∙ Li, W. Liu, S. Qian, S. Zhu, J. Selvaraj, J. N. Zhang, X.

Is the rate of adverse reaction to rabies vaccine in China really as the public thinks?—based on a meta analysis